Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | C1S | P09871 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008696 | 0.84 | ITGB3 (0.52) | ITGB3ITGA2BNOD1 | |
| SCHEMBL20008721 | 0.77 | ITGB3 (0.48) | ITGB3ITGA2BNOD1PRSS1 | |
| SCHEMBL20008719 | 0.77 | ITGB3 (0.48) | ITGB3ITGA2BNOD1PRSS1 | |
| SCHEMBL20008718 | 0.77 | ITGB3 (0.46) | ITGB3ITGA2BPRSS1 | |
| SCHEMBL20008720 | 0.73 | ITGB3 (0.44) | ITGB3ITGA2BNOD1F2PLG | |
| SCHEMBL20008713 | 0.73 | FTO (0.42) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL24592950 | 0.71 | NOD1 (0.57) | NOD1 | |
| SCHEMBL21172217 | 0.71 | NOD1 (0.57) | NOD1 | |
| SCHEMBL7336239 | 0.71 | ITGB3 (0.59) | ITGB3ITGA2BPRSS1 | |
| SCHEMBL24592946 | 0.70 | NOD1 (0.73) | NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | ITGB3 2592/4885ITGA2B 2485/4885NOD1 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.